NCT05740722 (Norseman) is a Phase 2 clinical trial of Nicotinamid riboside in Multiple Sclerosis, sponsored by Haukeland University Hospital.

Who is sponsoring NCT05740722?

NCT05740722 is sponsored by Haukeland University Hospital.

What drugs are being tested in NCT05740722?

Interventions in NCT05740722: Nicotinamid riboside, Placebo.

What condition does NCT05740722 study?

NCT05740722 studies Multiple Sclerosis, Progressive Multiple Sclerosis.

Is NCT05740722 still recruiting?

NCT05740722 is currently recruiting now. Last updated 11 January 2024.

Last reviewed 2024-01-11 · How we verify

NCT05740722: Norseman

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Recruiting now Phase 2 Last updated 11 January 2024

What this trial tests

Phase 2 trial testing Nicotinamid riboside in Multiple Sclerosis in 300 participants. Currently enrolling.

Timeline

3 May 2023

Primary endpoint
1 August 2027

30 December 2027

Quick facts

Lead sponsor	Haukeland University Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	300
Start date	3 May 2023
Primary completion	1 August 2027
Estimated completion	30 December 2027
Sites	1 location across Norway

Drugs / interventions tested

Nicotinamid riboside
Placebo

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Progressive Multiple Sclerosis — all drugs for Progressive Multiple Sclerosis →

Sponsor

Haukeland University Hospital

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis or Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The Roles of Caloric Restriction Mimetics in Central Nervous System Demyelination and Remyelination.
Kaffe D, Kaplanis SI, Karagogeos D. · · 2023 · cited 1× · PMID 38132442 · DOI 10.3390/cimb45120596
Insights into the therapeutic strategies for aging and aging-associated diseases.
Dong R, Wu Q, Kan J, Fu C, et al · · 2026 · PMID 42225652 · DOI 10.1038/s41392-026-02662-z
Energy-Metabolic Imbalance of Oligodendrocytes in Multiple Sclerosis: Mechanisms, Network Coupling, and Advances in Metabolism-Targeted Therapies.
Zhang Z, Kang J, Guo X, Jiang T, et al · · 2025 · PMID 41462894 · DOI 10.3390/biomedicines13122880
NAD<sup>+</sup> dyshomeostasis in RYR1-related myopathies.
Lawal TA, Riekhof W, Groom L, Varma P, et al · · 2025 · PMID 40846977 · DOI 10.1186/s13395-025-00390-6

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Haukeland University Hospital trials

Trials by the same sponsor.

NCT07450105 — Intensive Dialectical Behavior Therapy for Self-Harm and Suicidal Behavior in Youth: A Pilot Study · NA · not yet recruiting
NCT07450092 — Prehospital Use of Forced Air Warming · NA · enrolling by invitation
NCT07268716 — Assess the Efficacy of Tailored Patient Information and Voluntary Patient-managed Outpatient Digital Follow-up (I-POD) a · NA · not yet recruiting
NCT07392697 — The Intravenous Amino Acid Therapy for Vascular Rigidity in End Stage Renal Disease · NA · not yet recruiting
NCT07304219 — Physical Activity Based Treatment for Youth With Depression and Anxiety · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05740722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Haukeland University Hospital
Last refreshed: 11 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05740722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing